ClotProtect raises €670K Pre-Seed round

22 April 2024· Leeds, United Kingdom· health, defense, biotech, b2b, b2g, deep_hardware

To develop a molecule direct plasmin inhibitor intended to improve the treatment of severe bleeding by enhancing efficacy compared to existing treatments.

Taking part in the Elevate Her Accelerator was a turning point for ClotProtect. The support, mentorship and belief from the Lifted team, particularly from Jordan, has been instrumental in helping us secure Innovate UK funding and close this £1.2m round. This investment gives us the platform to scale faster and bring our technology to more patients who need it.

Helen Philippou, founder

Investors

Leado2h Ventures
Also participating
Science Entrepreneur ClubUniversity of Leeds

About ClotProtect

Stage
Seed
Headquarters
Leeds, United Kingdom
Founded
2024
Team Size
6–20
Sectors
healthdefensebiotechb2bb2gdeep_hardware

Source: https://o2hventures.com/seis-investment-by-o2h-ventures-in-clotprotect-therapeutics/